.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Baxter
Colorcon
Covington
McKesson
Queensland Health
Teva
McKinsey
Daiichi Sankyo
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,415,362

« Back to Dashboard

Which drugs does patent 8,415,362 protect, and when does it expire?


Patent 8,415,362 protects JAKAFI and is included in one NDA. There has been one Paragraph IV challenge on Jakafi.

This patent has ninety-five patent family members in thirty-three countries.

Summary for Patent: 8,415,362

Title:Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I: ##STR00001## that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE), Maduskuie; Thomas P. (Wilmington, DE), Wang; Haisheng (Hockessin, DE), Falahatpisheh; Nikoo (Wilmington, DE), Rafalski; Maria (Greenville, DE), Arvanitis; Argyrios G. (Kennett Square, PA), Storace; Louis (Middletown, DE), Jalluri; Ravi Kumar (Avondale, PA)
Assignee: Incyte Corporation (Wilmington, DE)
Application Number:12/138,082
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-001Nov 16, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-002Nov 16, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-003Nov 16, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-004Nov 16, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-005Nov 16, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,415,362

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,206,187Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase► Subscribe
7,598,257Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors► Subscribe
9,662,335Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors► Subscribe
9,079,912Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors► Subscribe
8,933,086Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors► Subscribe
8,946,245Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
8,541,425Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
8,530,485Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,415,362

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI553008► Subscribe
Taiwan201522344► Subscribe
TaiwanI468162► Subscribe
Taiwan201240663► Subscribe
TaiwanI410407► Subscribe
Taiwan200728275► Subscribe
Slovenia2474545► Subscribe
Slovenia2455382► Subscribe
Slovenia2426129► Subscribe
Slovenia2348023► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Cerilliant
McKesson
Queensland Health
Deloitte
AstraZeneca
Express Scripts
UBS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot